Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 28;9:807981. doi: 10.3389/fmed.2022.807981

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Les, Loureiro-Amigo, Capdevila, Oriol, Elejalde, Aranda-Lobo, Modesto, Güell-Farré, García, Murgadella-Sancho, Anniccherico, Martín-Fernández, Lorza, Monteys-Montblanch, Librero, Pintado-Lalueza, Delgado, Gracia-García, Sánchez-Álvarez, Pestaña-Fernández, Fanlo, Funalleras-Puig, Sarobe, Mediavilla and Ibero.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Temporal evolution of the study participants' inflammatory markers. These plots show the changes in the serial measurements of inflammatory laboratory parameters performed over a period of 14 days. Colored lines connect the mean value and black vertical lines indicate the confidence intervals of each measurement. Ten patients of the MPP group and another ten of the placebo group were treated with tocilizumab, a monoclonal antibody that blocks the IL-6 receptor and may cause a reactive increase in IL-6 plasma levels, within a median time of one day. MPP, methylprednisolone pulses; IL-6, interleukin-6; CRP, C-reactive protein.